B-cell chronic lymphocytic leukemia (B-CLL) is a common hematological malignancy that typically follows an indolent course over many years. However, with longer disease course and recurring anti-B-CLL therapy, in addition to yet undefined causes, transformation to aggressive B-cell lymphoma may occur. Coincidence of B-CLL with other hematological disorders has also been observed, nevertheless, the simultaneous appearance of B-CLL and multiple myeloma (MM) is a rare phenomenon. 1, 2 The clonal relationship between B-CLL and MM remains controversial. Two hypotheses have been postulated, either that both malignancies develop from two distinct clones, or that both evolve from the same B progenitor. To unravel the clonality of concomitant B-CLL and MM, different experimental strategies have been pursued. Early publications focused on different vs identical light chain (LC) expression in both diseases.
1 Hoffmann and Rudders 3 described a patient in whom B-CLL and malignant plasma cells (mPCs) expressed different LCs, suggesting a different clonal origin. Nevertheless, despite different LCs and immunglobulin (Ig) isotypes with B-CLL-cells expressing IgM kappa (k) and mPCs IgA lambda (l), Saltman et al. 4 postulated a monoclonal B-CLL/MM origin, as they detected identical heavy chain gene rearrangements in B-CLL cells and mPCs. The second approach to solve the clonal relationship is based on different cytogenetic aberrations discovered in B-CLL and MM. 5 As B-CLL and MM are difficult to examine by conventional cytogenetics (due to their low proliferation and metaphase quality), interphase fluorescence in situ hybridization (FISH) technology, together with simultaneous detection of cytoplasmatic LCs, have been used recently to prove a biclonal origin of both diseases. 2 In this study, we describe five Caucasian male patients with concomitant B-CLL and MM diagnosed at our center within a 4-year period . To resolve the clonal relationship, we combined Affymetrix (Santa Clara, CA, USA) single-nucleotide polymorphism (SNP) mapping array and FISH analyses on bone marrow (BM) smears. The SNP technology is highly efficient in the detection of recurrent and new chromosomal aberrations in B-CLL and MM, 6 and FISH on BM smears allowed us to connect specific chromosomal aberrations to different cell compartments.
Among our five patients, the first patient was a 64-year-old male, being evaluated in August 2005 because of weight loss, leukocytosis, anemia, foamy urine and increased creatinine. Detailed diagnostics revealed a Bence-Jones k-proteinuria, elevated serum k-LCs and via BM biopsy mPCs (40%) as well as lymphocytic infiltrates (45%). Immunohistology confirmed the simultaneous BM infiltration of mPCs and B-CLL cells. The diagnosis of concomitant MM stage IIIB (Salmon & Durie) and B-CLL stage Rai 0 was made (Supplementary Table 1 ). Identical unmutated clonal IgVH transcripts (VH 4-39) were present in both peripheral blood (PB) and BM cells ( Table 1) . As this transcript was cloned by amplifying mRNA of IgM (m) type and the vast majority of MM undergo class switch, it was postulated as derived from the B-CLL clone present in both PB and BM cells. The same transcript was detected with a low frequency in CD19 þ selected PB cells in December 2007, when the patient had stable MM and B-CLL diseases. LCs expressed by the B-CLL compartment were not measurable by flow cytometry. Copy number analyses using Affymetrix 50K and 250K NspI SNP arrays revealed no chromosomal aberration in unselected BM and CD19 þ selected PB cells (Table 1) . Despite rigorous analysis, the clonal relationship of concomitant MM/B-CLL in this patient remained unclear. Because of stage IIIB MM and B-CLL Rai 0 disease, he received two cycles of vincristine, doxorubicin, dexamethasone (VAD), PB stem cells (PBSCs) were mobilized with epirubicine, etoposide, cyclophosphamide (EVC), followed by an autologous PBSC (auto-PBSC) transplantation. According to European Group for Blood and Marrow Transplantation (EBMT) criteria, the patient obtained a partial remission of his MM, and has remained stable of both his MM and B-CLL with thalidomide maintenance therapy (Supplementary Table 2 ).
The second 76-year-old male patient presented with leukocytosis and IgG lambda (l) paraprotein in January 2006. Via BM biopsy, l-positive mPCs (30%) and k-positive B-CLL-infiltrates (10%) were detected. IgVH analysis from cDNA showed a mutated clonal transcript in PB cells. The 50K SNP assay performed on unselected PB cells revealed a 5.8 Mb deletion of the 13q14 region ( Table 1 ). The quality and quantity of the BM sample did not allow CD138 þ selection of mPCs, nevertheless, FISH using multicolor DNA probes on BM cytospins revealed deletion of at least two regions on chromosome 13 (one signal for 13q14 and one signal for 13q34) in 19 of 20 analyzed mPCs ( Figure 1a) . The DNA probe used in the 13q14 locus D13S319 overlapped with the 5.8 Mb deletion detected by the SNP array (UCSC Genome Browser, http://genome.ucsc.edu). However, the more telomeric DNA probe at 13q34 was outside the detected 5.8 Mb deletion, indicating monosomy of chromosome 13 in mPCs. Immunophenotyping showed different expression of LCs for B-CLL (k) and mPCs (l), suggesting biclonality of B-CLL and MM diseases. Because of concurrent stage Rai 0 B-CLL and stage IIIA MM by S&D, the patient received melphalan, prednisone (MP) and achieved a partial remission of his MM. At 17 months after the diagnosis of B-CLL and MM, the patient acquired acute myeloid leukemia (AML) (FrenchAmerican-British (FAB) M0), classified as therapy-induced (t-AML). The analysis of AML blast cells did not show del 13q14/monosomy 13, arguing for oligoclonality as well. Because of t-AML, mitoxantrone, etoposide, cytarabine (MICE) induction and consolidation chemotherapy was performed, achieving a complete remission. After 10 months, AML relapse occurred, and the patient eventually died of AML progression and septic complications. Autopsy revealed overt AML, but of note no MM or B-CLL residues (Supplementary Table 2 Table 1) . We performed FISH analyses on BM smears on 50 mPCs and all showed two signals for the chromosomal region 13q14, indicating the absence of del13q14; moreover, one MM subclone (40% of all evaluated mPCs) showed a clonal evolution with three signals for the centromere region of chromosome 11, implying trisomy 11 ( Figure 1b) . Two different genomic aberrations in different clonal cells indicated a biclonal origin of B-CLL and MM (Table 1) . High-dose dexamethasone was followed by two cycles of EVC. As the patient declined to receive an auto-PBSC transplantation, MP consolidation was performed, followed by thalidomide plus prednisone maintenance for 12 months. Owing to these anti-MM therapies, the patient's IgA paraprotein significantly decreased and his general condition improved (Eastern Cooperative Oncology Group (ECOG) 3-1). BM biopsy showed few mPCs (10%), and no persisting B-CLL infiltrates. Table 2 ).
The fourth patient was a 68-year-old male diagnosed with B-CLL in July 2003 (Supplementary Table 1 ). Because of stage Rai 0 B-CLL, no B-CLL-specific therapy was initiated. In November 2007, the patient developed Rai stage IV B-CLL cells (Rai IV) and fludarabine chemotherapy was begun. As a subsequent complication, the patient acquired recurrent septic infections due to pronounced granulocytopenia. BM reanalysis showed 50% B-CLL cells and 40% coexisting monoclonal k-expressing mPCs. Differently mutated clonal IgVH transcripts, VH4-34 and VH1-18, were present in CD19 þ PB and CD138 þ BM cells, respectively, strongly implying a biclonal origin of both diseases (Table 1) . Copy number analysis with 250K NspI SNP arrays was also performed on CD19 þ selected PB cells and CD138 þ selected BM cells. No aberrations were detected in B-CLL cells ( Figure 1c , left panel), but a complex molecular karyotype in mPCs (including gain on 4pter-p15.2 and 11q13.1-24.1, and deletions on 10q24.2-25.2, 12pter-p12.3 and 17p13.1-p12; Figure 1c , right panel), verified the biclonal origin of B-CLL and MM. As both B-CLL and MM diseases were aimed to be treated and fludarabine response had been disappointing, cyclophosphamide, thalidomide and dexamethasone was given and the patient transferred to our department in February 2008. A skeletal survey showed multiple osteolytic lesions and BM revealed dense B-CLL persistence, whereas mPCs remained stable. Because of a loss of CD5 coexpression on B-CLL cells, occurrence of Richter transformation was suggested. Rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) was given and due to persistence of pancytopenia and dense B-CLL-infiltrates, R-bendamustin thereafter. This not only led to a marked decrease of BM B-CLL and mPC infiltrates, but also to prolonged BM aplasia. As the patient's general condition decreased (ECOG 2-3) and BM aplasia prohibited chemotherapy continuation, he was discharged home with best supportive care measures. He deceased 3 months thereafter with B-CLL progression (Supplementary Table 2 ).
The fifth patient was a 60-year-old male diagnosed with B-CLL in September 2003 (Supplementary Table 1 ). In February 
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2005, white blood cell increased to 107 Â 10 9 /l and the BM showed 90% CD20 þ B-CLL infiltrates (Figure 1d) . After 2 months, the patient presented with increased splenomegaly, anemia and thrombocytopenia. Owing to assumed B-CLL progression, chemotherapy with chlorambucil and prednisone was initiated, but did not improve the patient's condition (ECOG 3). In July 2005, urine immunoelectrophoresis and serum protein electrophoresis revealed monoclonal l-SFLCs (serum free light chain), and the typical MM phenotype with l-LC-expressing mPCs (Figures 1e-g) . A skeletal survey showed multiple lytic lesions, and renal impairment became apparent. On the basis of increasing serum and urine l-LCs, atypical BM mPCs (Figures 1e-g ), lytic bone lesions and renal insufficiency, symptomatic stage IIIB MM was diagnosed. Molecular analyses of PB and BM cells identified two unmutated IgVH gene rearrangements ( Table 1 ). The VH3-9 transcript was presumably derived from his B-CLL, as it was amplified from cDNA of PB MNCs. An additional VH3-15 rearrangement could be amplified only from genomic DNA, which was not possible for the VH3-9 rearrangement. Sequence analysis of both clonal rearrangements revealed a point mutation in the familyspecific VH3 primer binding site of the VH3-9 rearrangement as well as a stop codon in the CDR3 region of the VH3-15 rearrangement. Whereas the first mutation was likely to abolish the amplification from DNA, the latter could lead to nonsensemediated mRNA decay, which may explain the absence of the VH3-15 transcript and the missing heavy chain protein in the immunofluorescence assay ( Table 1) . As both clonal rearrangements were identified in PB cells, they were most likely derived from the B-CLL clone lacking allelic exclusion. Copy number analysis with 50K SNP arrays identified two deletions on chromosome 11 (11q23 and 11q24) in unselected BM and PB cells (Table 1) . FISH with an ATM probe confirmed the deletion of chromosome 11q23 in 89% of unselected BM cells, thus representing the B-CLL clone given the frequency of 90% of B-CLL cells in the BM at the time of analysis (Figure 1h ). Moreover, a small fraction of BM cells (2.5%) showed tetrasomy of chromosome 11 (four signals for ATM and four signals for centromere 11 (Figures 1h and i ). An expression array analysis with this sample showed high cyclin D1 expression in unselected BM cells (data not shown), indicative for an aberrant expression due to a translocation event. We performed an additional FISH with a probe for t (11;14) in unselected BM cells and detected a small percentage of interphase nuclei (4%) with the t(11;14), together with one additional signal for cyclin D1 (Figures 1h and j) . This correlated with giant, multinucleated mPCs by May-Grü nwaldGiemsa staining (Figure 1g ), which were hyperdiploid for chromosome 11 (data not shown). This mPC fraction had a different genomic aberration than B-CLL cells, confirming the biclonal origin of B-CLL and MM in this patient also. Chemotherapy with cyclophosphamide was initiated, but BM mPC infiltrates increased to 90% and l-SFLCs remained elevated, whereas B-CLL infiltrates completely disappeared. Two cycles of VAD were given and the patient underwent auto-PBSC transplantation in October 2005. Thereafter, his general condition improved (ECOG 3-2) and l-SFLCs decreased substantially. Bortezomib maintenance therapy was initiated, but in February 2006 MM relapse occurred and the patient died of myeloma progression and severe pneumonia 2 months later, whereby of note, his previous B-CLL remained in complete remission (Supplementary Table 2 ).
As explicitly demonstrated in these five patients, the clinical picture of patients with B-CLL and MM was the combination of typical features of both diseases. Of note, patients with concomitant B-CLL and MM seemed to have a more unfavorable MM course, showing adverse prognostic features and early death due to myeloma progression. 1 As one promising therapeutic approach for both diseases, high-dose chemotherapy and auto-PBSC transplantation have been performed in selected patients, which also proved helpful in our patients #1 and #5. Another important finding is, that under certain circumstances, a third neoplasia or CLL transformation may occur (AML in patient #2 and Richter's syndrome in patient #4). In most previously reported patients, MM developed during the course of B-CLL (in 3/5 of our patients), arguing for mechanisms of a causal relationship. Although it has been described that B-CLL cells can differentiate further and acquire mPC characteristics, our findings strongly argue against this possibility. The largest published group of B-CLL/MM patients supports our conclusion showing a coexistence of two distinct clonal expansions in six patients based on a different Ig LC in B-CLL and MM cells. 1 Our results also show that the simultaneous occurrence of MM and B-CLL is a rare phenomenon, but that other oligoclonal malignancies are associated with B-CLL. The occurrence of AML has been described in a previously untreated B-CLL patient, although we are not aware of AML with concomitant B-CLL and MM in any patient as yet. 7 Other hematological malignancies observed in conjunction with B-CLL are prolymphocytic leukemia, Hodgkin's lymphoma, myelodysplastic syndrome and non-Hodgkin's lymphomas. [1] [2] [3] [4] [5] 7 Our calculation of the prevalence of concomitant B-CLL and MM within 348 B-CLL and 374 MM patients treated within in our institution between 2005-08 was 1.44 and 1.34%, respectively, suggesting that concomitant B-CLL and MM is indeed a rare phenomenon, but may be discovered more frequently today with the use of better diagnostic options for both diseases.
During early lymphoid differentiation, the Ig gene rearrangements generally follow a hierarchical order. 8 Ig heavy chain gene (IGH) rearrangement precedes Ig LC gene rearrangement, and DH to JH joining precedes VH to DJH joining. 9 The process of allelic exclusion ensures that once a functional VDJH rearrangement has been achieved, the other IGH allele is generally excluded from further recombination attempts. 10 After this process, the Ig LC loci proceed to rearrange; initial attempts occur at the Ig k locus (IGK), and if a functional IGK rearrangement is not achieved, the Ig l locus (IGL) undergoes recombination. Without further molecular analyses, a biclonal origin solely based on different LC types may mistakenly be assumed. 1 Most previous reports have indeed focused on heavyand LC similarities vs discrepancies to explain the mono-vs biclonal origin, respectively: in 13 of 23 (56%) published B-CLL/MM cases, B-CLL and MM cells shared different LCs, suggesting a biclonal origin of both diseases. [1] [2] [3] [4] [5] 7 However, identical LCs do not necessarily support monoclonality in B-cell malignancies, because of inconclusive immunophenotyping (as observed in patient #1), or demonstration through genotype analyses that both B-CLL and MM are biclonal, despite identical LCs (as observed in patient #3). Additional analyses have been used to resolve the clonal origin of B cells in B-CLL/ MM patients. Most of them are based on the detection of genomic abnormalities in B-CLL and MM cells. We used SNP arrays as a new screening method in the detection of chromosomal imbalances of selected B-CLL and MM cells. As this technology depends on around 30% aberrant cells for an imbalance to be detected, highly enriched cell populations allow the assignment of identified aberrations to the respective cell compartment, as could be demonstrated in patient #4. However, when only one tumor cell type can be enriched, or B-CLL and MM cells cannot be separated because of limited cells or sample availability (as in patients #2, #3 and #5), identical aberrations have to be related to the two cell compartments to prove clonality. Our rationale in those patients was to use SNP mapping arrays from CD19 positively selected PB cells for the screening of genomic aberrations in B-CLL and subsequent FISH on BM smears to confirm the presence of these aberrations in mPCs. The SNP arrays from unselected and CD19 þ selected PB cells were highly informative in four patients. One mono-and one biallelic deletion of chromosome 13q14 was detected in patients #2 and #3, respectively. Nevertheless, as del13q14 is the most frequent chromosomal abnormality in both B-CLL (in 450%) 11 and MM (via FISH in 40-50%), additional FISH with probes from 13q34 outside the deleted 5.8 Mb region clearly showed that both regions were deleted in almost all analyzed mPCs. Therefore, two different chromosomal aberrations (del13q14 in PB cells and monosomy 13 in mPCs) strongly indicated a biclonal origin of B-CLL and MM also in patient #2. The biallelic deletion of 13q14 in CD19 þ cells from patient #3 with two differently sized alleles (5.6 and 2.7 Mb) was not detected in mPCs on BM slides. Instead, a trisomy of chromosome 11 was discovered in 40% of mPCs, disclosing a biclonal origin of both cell populations. Both aberrations have an intermediate prognosis 12 and explain the achievement of stable disease of both B-CLL and MM in this patient. The two large 11q deletions (15.4 and 5.5 Mb) detected in B-CLL cells of patient #5 span the ATM and ADAMTS 8/15 genes, respectively. Moreover, we suggest that t (11;14) detected by FISH at B-CLL diagnosed in a small fraction of unselected BM cells (o5%), accompanied by a high cyclin D1 expression, led to the expansion of the mPC clone. The genomic abnormalities discovered in mPCs of patient #4 were recurrent for MM; however, the complex karyotype with gain on 11q and 4p, together with losses on 10q, 12p and 17p (including p53), assigned patient #4 as high risk. 13 Our study bears the limitation that analyzed consecutive MM/CLL patients were retrieved from a single institution rather than from registry data from many centers. Our analysis, however, also has many strengths, such as: (1) use of the combined Affymetrix SNP mapping array and FISH analyses on BM smears, whereby SNP revealed recurrent and new chromosomal aberrations in B-CLL and MM, and FISH connected specific chromosomal aberrations to different cell compartments; (2) the thorough assessment of concomitant CLL/MM in a large cohort of consecutive MM and CLL patients; and (3) our comprehensive analysis of this formerly presumed rare condition, aiming to increase the awareness of both diseases occurring in one patient, and clearly demonstrating through molecular analyses that both diseases are biclonal. Our in-depth study also suggests that the concomitant occurrence of more than one hematological neoplasia may evolve as a special condition of the BM microenvironment. An intriguing possibility would be that leukemic B cells may secrete relevant factors that 'trigger' other B cells or mPCs. 1 The presence of monoclonal B-cell populations recently discovered in the PB of apparently healthy individuals 14 support the 'multi-hit' hypothesis of oncogenesis and suggest that the monoclonal 'B-CLL-phenotype' cells could be a starting point in the cascade of different events responsible for leukemogenesis. The mechanisms involved in B-cell leukemias are unknown at present, but it is tempting to speculate that infectious agents associated with certain susceptibility genes may trigger polyclonal B-cell proliferation, with the subsequent evolution of cytogenetically distinct clones.
We read with interest the article by Cortelezzi et al.
1 published in a recent issue of this journal. They report their experience with low-dose subcutaneous alemtuzumab (10 mg three times per week for 18 weeks) in 49 patients with pretreated B-cell chronic lymphocytic leukemia (B-CLL). The rationale for the use of subcutaneous low-dose alemtuzumab was to reduce the profound lymphopenia and high risk of infections when using the conventional intravenous schedule (30 mg three times a week for 12 weeks), which are serious problems particularly in older chronic lymphocytic leukemia patients and those already severely immunocompromised by advanced disease and earlier therapies. The authors show interesting data regarding the efficacy of low-dose alemtuzumab in terms of response rate, progression-free survival, time to retreatment, and a favorable toxicity profile in a group of poor prognosis patients.
We now report our clinical experience with low-dose alemtuzumab in 19 heavily pretreated chronic lymphocytic leukemia patients. Twelve of these patients, who have been previously reported, received intravenous low-dose alemtuzumab (10 mg three times a week) in ten weeks. 2 Seven additional patients were subsequently treated with the same schedule, except that alemtuzumab was administered subcutaneously to reduce infusion related toxicity. 3, 4 All patients had progressive disease according to NCI-WG criteria at the time when treatment with low-dose alemtuzumab was started. Eighteen patients had previously received alkylating agents-based therapy, 15 fludarabine-containing regimen, 4 rituximab-containing regimen and 2 autologous PBSCT (median number of previous treatments 2, range 1-6). Eight patients were fludarabine refractory. Median age of the patients was 62 years (range 50-78 years), 13 were male and 6 female.
Sixteen patients completed the planned treatment. Two patients discontinued the treatment prematurely for documented progressive disease and 1 because of the development of a second malignancy. Assessment of response, according to NCI-WG criteria and including a BM biopsy in all responding patients, was performed 2 months after the end of the treatment. Overall survival, time to progression and time to retreatment were calculated from the start of alemtuzumab treatment to the event.
Three patients (16%) obtained a complete response (CR) and 6 (31%) obtained a partial response (PR), with an overall response rate of 47% (Table 1) . Two of the remaining patients experienced progressive disease shortly after the end of the treatment, whereas 5 patients had stable disease. Of the 5 patients with 17p-karyotype, 1 obtained a complete response and another a partial response, whereas only 1 of the 8 fludarabine-refractory patients achieved a partial response. The response rate according to other clinical and biological features is reported in Table 1 .
Except for grade IV neutropenia requiring G-CSF in 4 patients and grade IV anemia requiring red blood cell transfusions in 2 patients, therapy was well tolerated both by patients who received subcutaneous and patients who received intravenous alemtuzumab. Other hematological and extra-haematological side effects were relatively mild and consisted of fever, itching, rigor, headache and hypotension. No episode of febrile neutropenia or bacterial/fungal infection occurred during treatment. Nine patients (47%) showed cytomegalovirus (CMV) reactivation after a median of 6 weeks of treatment, when the median lymphocyte counts were 140/mmc. Treatment was temporarily interrupted and patients were successfully treated with oral ganciclovir for a median of 14 days.
After a median follow-up of 33 months, 10 patients (52%) died with a median overall survival of 29 months. Only 2 of these patients responded to the treatment. The other 7 responding patients experienced progression of the disease. The median progression-free survival was 11 months (range 5-45 months). Thirteen patients, 5 responders and 8 nonresponders, received further treatment. The median treatmentfree survival was 20 months (range 6-70 months). Table 1 Patients' clinical and biological characteristics and response to therapy CR, complete response; M, mutated; n, number; OR, odds ratio; PD, progressive disease; PR, partial response; SD, stable disease; U, unmutated; FISH, Fluorescence In Situ Hybridization.
